Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Atezolizumab with chemotherapy improves PFS in squamous NSCLC

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 02.06.18
Views: 735

Dr Robert Jotte - Rocky Mountain Cancer Centers, Denver, USA

Dr Jotte speaks with ecancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting about treating stage IV squamous NSCLC with anti-PD-L1 atezolizumab and chemotherapy.

In this study, 29% of all patients, regardless of PD-L1 expression, had a reduced risk of disease worsening or death, compared with those who received chemotherapy alone.

He also describes a doubling of progression-free survival (PFS) benefit with this combination, noting that this came with an increased rate of severe side effects.

For more on these results, watch his interview with ecancer, and read our news coverage here.

Slides from this presentation are available here.

Related videos

follow us

Donate to ecancer

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation